Filing summary
Registrant and period: The supplied filing is Targacept, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015, not a filing identified as Gyre Therapeutics, Inc. Investors should verify the company and filing identity.
Business context and reporting period
Targacept was a clinical-stage biopharmaceutical company whose historical focus was neuronal nicotinic receptor (NNR) drug candidates. Following disappointing clinical results, it had no plans to continue internal development of those programs and was seeking to sell or out-license the assets. The company had entered a proposed merger with Catalyst Biosciences on March 5, 2015. Results compare the three months ended March 31, 2015 with the same period in 2014.
Financial results and liquidity
| Metric | Q1 2015 | Q1 2014 or prior balance |
|---|---|---|
| Revenue | $0.06 million | $0.087 million |
| Research and development expense | $2.34 million | $9.08 million |
| General and administrative expense | $3.387 million | $2.763 million |
| Reduction-in-force expense | $1.156 million | None |
| Operating loss | $6.823 million | $11.756 million |
| Net loss | $6.752 million; $0.20 per share | $14.999 million; $0.44 per share |
| Cash used in operations | $4.447 million | $14.846 million |
| Cash and cash equivalents | $73.113 million at March 31 | $56.430 million at December 31, 2014 |
| Cash, cash equivalents and marketable securities | $106.3 million at March 31 | $110.8 million at December 31, 2014 |
| Total assets | $107.136 million at March 31 | $111.999 million at December 31, 2014 |
| Total liabilities | $3.903 million at March 31 | $2.914 million at December 31, 2014 |
Revenue was minimal, and no collaboration license or milestone revenue was recorded in either quarter. Gross margin is not presented and is not meaningful from the information provided. The company reported no long-term debt on the balance sheet. Current assets were $105.236 million versus current liabilities of $3.903 million at March 31, 2015.
Investing activities provided $21.037 million, primarily reflecting sales of marketable securities; financing activities provided $0.093 million. Cash and cash equivalents increased by $16.683 million during the quarter. The company said its existing capital resources were expected to fund operations through completion of the proposed merger.
Material changes versus prior comparable period
- Net loss narrowed by $8.247 million, mainly as R&D expense fell $6.740 million following completion of major TC-5214 and TC-1734 studies in 2014, and income tax expense fell from $3.412 million to $0.021 million. The 2014 tax charge related to an IRS examination and excess stock-option tax deductions.
- G&A expense rose $0.624 million, primarily due to $1.2 million of merger-related legal, finance, business-development and consulting costs.
- The first-quarter 2015 reduction in force cut the workforce by five employees, approximately 28%; the company reported 13 employees at quarter-end. The $1.156 million charge included severance and accelerated stock compensation.
- Revenue declined $0.027 million, reflecting lower grant and other revenue; the filing reported no collaboration revenue in either period.
Outlook, risks and unusual items
- The proposed merger contemplated existing Catalyst holders owning approximately 65% and Targacept holders approximately 35% of the combined company, subject to transaction conditions. Targacept also planned a pre-closing distribution that included about $37 million in redeemable convertible notes, approximately $20 million in cash, and an interest in a liquidating trust for remaining NNR assets.
- After quarter-end, Pfizer gave Catalyst notice terminating its research and license agreement, effective June 1, 2015. Targacept said the merger evaluation was ongoing; the development delayed the expected closing beyond Q2 2015 and could reduce the cash dividend below $20 million while adding costs. The filing does not establish the ultimate effect on the merger.
- Management expected substantially lower program-related R&D expense for the rest of 2015 after completing the TC-6499 exploratory trial in April; no further clinical studies were planned. The company said future losses were expected.
- Risks include failure or delay of the merger, a possible $3.22 million termination fee and up to $1.25 million reimbursement of certain Catalyst expenses under specified circumstances, dilution and reduced Targacept-holder influence, uncertainty over note redemption, and uncertain value and proceeds from NNR assets. The company also cited Nasdaq initial-listing requirements, including the $4.00 minimum bid-price requirement, and anticipated a possible reverse stock split.
- Cash and investments were principally in cash accounts, money-market funds and high-quality marketable securities. Management estimated that an immediate uniform 10% increase in interest rates would not materially affect portfolio fair value. No material contingencies beyond those described are quantified in the supplied filing text.
Important facts for investors to verify
- Confirm the filing belongs to Targacept, Inc.; the request metadata names Gyre Therapeutics, Inc.
- Check subsequent filings for the merger’s status and final terms after Pfizer’s termination notice, including any changes to the expected cash distribution and closing date.
- Verify actual cash burn, merger-related spending and liquidity against the stated expectation that resources would last through merger completion.
- Review the final treatment of the $37 million notes, the NNR liquidating trust, and any realized proceeds or trust expenses.
- Check the status of Nasdaq listing compliance, any reverse stock split, and the potential availability of tax-loss carryforwards after ownership changes.